<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962026</url>
  </required_header>
  <id_info>
    <org_study_id>IL1T-AI-1022</org_study_id>
    <nct_id>NCT00962026</nct_id>
  </id_info>
  <brief_title>Rilonacept in Diabetes Mellitus Type 1: Safety Study</brief_title>
  <acronym>RID-A</acronym>
  <official_title>A Phase I, Open-label, Safety Study of Anti-inflammatory Therapy With Rilonacept in Adolescents and Adults With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <brief_summary>
    <textblock>
      This study is being done to see if an investigational drug called rilonacept is safe to use
      in patients with type 1 diabetes, and if it can slow the loss of the body's ability to
      secrete insulin in patients who are still able to make a small amount of insulin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of infection in study participants</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of other adverse effects in study participants</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in participants' sex steroids (testosterone/estradiol)</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in participants' HbA1c levels, insulin doses, and beta cell preservation</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Rilonacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilonacept</intervention_name>
    <description>Rilonacept given subcutaneously, dose per package labeling, once weekly.</description>
    <arm_group_label>Rilonacept</arm_group_label>
    <other_name>Arcalyst, IL-1 Trap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Within 5 years of diagnosis of type 1 diabetes

          -  Between the ages of 16 to 45 years

          -  Have at least one diabetes-related autoantibody present

          -  Have mean C-peptide level &gt; 0.2 nmol/L on a mixed meal tolerance test

          -  Be taking insulin

          -  Complete written informed consent

        Exclusion Criteria:

          -  Taking inhaled or oral steroids (for example Advair, Orapred)

          -  Have an active infection

          -  Have serologic evidence of HIV, Hepatitis C, Hepatitis C, or tuberculosis

          -  Have ongoing use of medications known to affect glucose tolerance

          -  Have a live vaccine 90 days prior to, or during this study

          -  Taking any other experimental medication within the past 28 days

          -  Have prior treatment with rilonacept

          -  Have any complicating medical issues or abnormal clinical laboratory blood counts or
             results that interfere with study conduct; history of malignancies

          -  Pregnant or lactating females

          -  Males and females unwilling to use an acceptable method of contraception for the
             duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perrin C White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>February 21, 2014</last_update_submitted>
  <last_update_submitted_qc>February 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Perrin C White</investigator_full_name>
    <investigator_title>Director of Pediatric Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Interleukin 1</keyword>
  <keyword>Type 1 diabetes mellitus</keyword>
  <keyword>Rilonacept</keyword>
  <keyword>Arcalyst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

